Services aux conférences Mandl

Résumé: CHI’s successful Alliance Management Congress is growing! Our growth mirrors recent survey results collected from eighty-nine thought leaders in alliance management, diagnostics, medical devices, and licensing. In light of the economy and state of industry, 88% deem alliances as critical and essential to their organization’s alliance activity. During the next 9-12 months, 84% will grow their alliances with new partners including those from academic institutions, diagnostics, medical devices, and international markets. The Collaborations, Deals, and Alliances Congress will house the 7th Annual Alliance Management Congress, the inaugural conference on Collaboration and Deal Making Strategies to Commercialize Molecular Diagnostics, and the 2nd Annual Combination Drug Therapies: Overcoming Challenges in the Development of Fixed Dose and Co-Packaged Combinations. The Collaborations, Deals, and Alliances Congress is for Vice Presidents, Department Heads, Directors, and Managers of Alliance Management, Business Development, Licensing, R&D, Project Management, Clinical Development, and Drug Regulatory Affairs from pharmaceutical, biotech, diagnostics, and medical devices companies. The Collaborations, Deals, and Alliances Congress offers novel case studies, strategies, and techniques from thought leaders who have real-world perspectives to share. There will be case studies of best practice examples, keynotes, industry trends and updates, interactive discussion groups, and panel discussions. The Collaborations, Deals, and Alliances Congress offers multiple conference tracks that provide education for an individual’s area of interest. The Collaborations, Deals, and Alliances Congress also offers joint sessions between the tracks and networking opportunities to provide cross-disciplinary learning.

Résumé: The course is comprised of lectures, delivered by leading experts in each field of ADME, interspersed with interactive workshops centred around practical examples demonstrating how in vitro data generated during drug development can be used to predict:

• Metabolic drug clearance (CL)
• Metabolic drug-drug interactions (DDIs)
• Gut first-pass metabolism
• Oral drug absorption incorporating food effects and the impact of dosage form
• Effect of transporters and enterohepatic recirculation on kinetics
• Drug distribution to different organs
• Population variability in drug concentration-time profiles
• Variation in kinetics in specific populations (paediatrics, ethnic groups, various disease populations)
• Time-course of drug in plasma that fits observed clinical data (achieved using fitting modules within physiologically-based pharmacokinetics (PBPK) models combined with drug specific in vitro information.)

Résumé: Over 400 thought leaders from 200+ organizations, representing 21 countries, gathered at the Biomarker World Congress 2009 (May 27-29 in Philadelphia) to discuss the biomarker impact on Personalized Medicine, Clinical Pharmacology, Translational Medicine, Molecular Diagnostics, Safety Assessment, Clinical Trials, Assay Development, Go/No-Go Decision Making and Oncology in Drug & Diagnostics. The level of energy and participation reflected the booming interest in this field. Comprehensive Coverage of Biomarkers in: Personalized Medicine, Clinical Pharmacology, Translational Medicine, Molecular Diagnostics, Safety Assessment, Clinical Trials, Assay Development, Biomarker Qualification, Oncology Drugs & Diagnostics

Résumé: Conference Program Include: Evaluating Novel Technologies for Cell Based Screening, Monitoring Cardiotoxicity and Drug Safety, Targeting Pain with Novel Therapeutics, New Tools for Detecting Nephrotoxicity, Successful Targeting of Alzheimer's Disease, Pharmacology Driven Assays for Current Targets, Integrated in vivo Molecular Imaging in Drug Discovery & Development, Early Assessments for Predicting Hepatotoxicity

Résumé: Cambridge Healthtech Institutes Collaborative Innovation in Biomedicine aims to bring together a number of experts with practical experience in organizing, managing, funding, and getting results from such projects. While there are real challenges with shared resources, IP protection, differing goals, and finding ways to equalize value contributions and benefits gains, some of the biggest challenges are based on firmly held beliefs about the risks of working together and narrow conceptions of what really constitute pre-competitive space. A key goal of the program is to provide attendees with a number of key strategies for identifying when and how collaborative innovation can and should be encouraged.

Résumé: Structure-Based Drug Design (SBDD) has been in use within the pharmaceutical industry for over twenty-five years. SBDD continues to play an important role in drug discovery, design, and optimization. Moreover, with the development of sophisticated biophysical and computational methodologies, SBDD is impacting hit identification and hit to lead optimization approaches across the industry. In this program, we wish to highlight some recent breakthrough stories and successes using SBDD driven by medicinal chemistry, computational and biophysical approaches.

Résumé: The Pharma CI Conference & Exhibition is the largest and best gathering of senior level pharma, biotech, medical device, and diagnostic executives in competitive/business intelligence.

Résumé: Welcome to the 6th annual Ion Channel Targets conference and exhibition. This year's event takes place in Washington, capital city of the United States. The conference will be co-located with Probe Discovery. Registered delegates will have access to both meetings ensuring a very cost-effective trip. Agenda Topics Ion Channels in Drug Discovery Target Identification and Validation Advances in Ion Channel Technology Ion Channels & Drug Safety (including hERG) Outsourcing Ion Channels in Disease Biology Transporter Protein Sponsorship and Exhibition

Résumé: Welcome to the 2nd annual Probe Discovery conference and exhibition. This year's event takes place in Washington, capital city of the United States. The word 'probe' is a broad term which can be interpreted to mean any one of a wide variety of agents. These include active chemistries discovered in academic screening labs or in government (MLPCN or the NIH), commercially available probes (i.e. dyes, antibodies, fluorescent proteins), failed drug candidates from Pharma, whole body or cellular imaging agents, specific biomarkers or tool molecules from chemogenomics and/or systems biology efforts. The goal of this conference is to bring all of the various incarnations of probe hunters together to share experience and network to a common purpose. The conference will be co-located with Ion Channel Targets. Registered delegates will have access to both meetings ensuring a very cost-effective trip. Confirmed Speakers Hakim Djaballah, Director, Memorial Sloan Kettering Cancer Centre Rathman Chaguturu Director, University of Kansas Peter Brown Project Manager, University of Toronto Agenda Topics Failed Drug Candidates as Probes Dyes, Antibodies and Fluorescent Proteins Whole Body or Cellular Imaging Agents Tool Molecules from Chemogenomics Innovative Assay Technologies for Probe Discovery

Résumé: Welcome to the 2nd annual Microarray World Congress where you will hear about the latest developments and applications in the rapidly expanding field of microarrays. This year's event will be held in San Diego. The conference will be co-located with the Lab-on-a-Chip World Congress, Molecular Diagnostics World Congress and Single Cell Analysis Summit. Registered delegates will have access to all four meetings ensuring a very cost-effective trip. Make the most of your trip by also attending the pre-conference training courses. Confirmed Speakers: Thomas Joos, Head, Biochemistry/NMI Natural and Medical Sciences Institute at the University of Tuebingen Steve Blair Associate Professor, Unviersity of Utah Bill Robinson Assistant Professor, Stanford University Seth Crosby Director, Washington University Martin Dufva Associate Professor, Technology University of Denmark Agenda Topics CGH Arrays ChIP-on-ChIP Bioinformatics for microarrays Methylation Detection Protein and Antibody Arrays Lipid Arrays Tissue Arrays Emerging Technologies

Résumé: Welcome to the 2nd annual Lab-on-a-Chip World Congress, to be held in San Diego. The conference will be co-located with the Microarray World Congress, Molecular Diagnostics World Congress and Single Cell Analysis Summit. Registered delegates will have access to all four meetings ensuring a very cost-effective trip. Confirmed Speakers: Andreas Manz, Head of Research - KIST Europe Hur Koser Professor, Yale University Holger Becker Director, Microfluidic ChipShop Nicole Pamme Senior Lecturer, Hull University Jon Cooper Professor, Glasgow University Frederic Breussin Analyst, Yole Development Mehmet Yanik Professor, Massachusetts Institute of Technology Agenda Topics: Point-of-care diagnostics New applications Advances in microfabrication and engineering

Résumé: Welcome to the 3rd annual Molecular Diagnostics World Congress, this year's event will be held in San Diego. The conference will be co-located with the Lab-on-a-Chip World Congress, Microarray World Congress and Single Cell Analysis Summit. Registered delegates will have access to all four meetings ensuring a very cost-effective trip. Make the most of your trip by also attending the co-located Market Analysis & Business Tutorial. Confirmed Speakers: Norman Nelson, Director of Biochemistry, Gen-Probe John Quackenbush, Professor, Harvard School of Public Health Mike Makrigiorgos Associate Professor, Dana Farber Cancer Institute Vladimir Tolstikov Director, UC Davis Enal Razvi Biotech Analyst, Select Biosciences Stephen Bodovitz Principal, Bio Perspectives Shana Kelley Professor, University of Toronto Agenda Topics Molecular Diagnostics & Biomarkers PGx and Personalized Medicine Emerging Technologies Clinical Applications of Molecular Diagnostics Commercial & Regulatory Perspectives

Résumé: Welcome to the inaugural Single Cell Analysis Summit, to be held in La Jolla, San Diego. The conference will be co-located with the Lab-on-a-Chip World Congress, Microarray World Congress and Molecular Diagnostics World Congress. Registered delegates will have access to all four meetings ensuring a very cost-effective trip. Make the most of your trip by also attending the co-located Market Analysis & Business Tutorial. Confirmed Speakers: Jay Groves, Associate Professor, University of California Garry Nolan, Professor, Microbiology and Immunology StaHerbert Fritsche, MD Cancer Centre James Reuben Professor, University of Texas Laurie Jackson-Grusby Assistant Professor, Childrens Hospital Boston Oscar Ces Imperial College London Robert Murphy Professor of Biological Sciences, Carnegie Mellon University Steven Bodovitz Principal, BioPerspectives Peter Howell Principle Scientist Naval Research Laboratory Nathaniel Cady Professor, Cady Research Group, University of Albanynford Cancer Centre Agenda Topics Microarrays and Chips for Single Cell Analysis Label-Free Routes to Single Cell Analysis RT-qPCR in Single Cell Analysis Single Cell Analysis in Genetic Disorders Microfluidics and Single Cell Analysis Single Cell Analysis in Signaling

Résumé: This satellite to the 2010 meeting of the Society for Neuroscience is a joint venture between Neuropharmacology and NC-IUPHAR that will highlight how emerging structural data are providing new insights into the molecular properties of receptors, ion channels and transporters, revolutionizing pharmacological concepts, and leading to new ideas of drug discovery and development.